ES2072424T3 - Formula y metodo para el tratamiento de hipertrofias prostaticas benignas. - Google Patents

Formula y metodo para el tratamiento de hipertrofias prostaticas benignas.

Info

Publication number
ES2072424T3
ES2072424T3 ES90902952T ES90902952T ES2072424T3 ES 2072424 T3 ES2072424 T3 ES 2072424T3 ES 90902952 T ES90902952 T ES 90902952T ES 90902952 T ES90902952 T ES 90902952T ES 2072424 T3 ES2072424 T3 ES 2072424T3
Authority
ES
Spain
Prior art keywords
benign prostatic
composition
preferably comprises
hypertrophies
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90902952T
Other languages
English (en)
Inventor
Muharrem Gokcen
Terry J Guy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunolytics Inc
Original Assignee
Immunolytics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunolytics Inc filed Critical Immunolytics Inc
Application granted granted Critical
Publication of ES2072424T3 publication Critical patent/ES2072424T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

LA INVENCION SE REFIERE A UNA COMPOSICION Y UN METODO PARA TRATAR LA HIPERTROFIA PROSTATICA BENIGNA EN LOS MAMIFEROS DE MANERA QUE SE PROVOQUE LA DISOLUCION Y LA REGRESION DEL TEJIDO PROSTATICO HIPERTROFIADO CON LO QUE SE ALIVIA LOS SINTOMAS DE OBSTRUCCION ASOCIADOS A LA ENFERMEDAD. LA PRESENTE COMPOSICION COMPRENDE PREFERENTEMENTE UNA SOLUCION LIBRE DE PIROGENO ESTERIL DE LA COLAGENASA DE ENZIMAS HIDROLITICAS E HIALURONIDASA , UN SURFACTANTE NO IONICO, Y UN ANTIBIOTICO; TODO PREVISTO EN UN PORTADOR ACUOSO ISOTOMICO, TAMPONADO, FARMACEUTICAMENTE ACEPTABLE. EL PRESENTE METODO COMPRENDE PREFERENTEMENTE LA INYECCION INTRAPROSTATICA DIRECTA DE UNA DOSIS TERAPEUTICAMENTE EFECTIVA Y SEGURA DE LA COMPOSICION POR VIA DE ADMINISTRACION TRANSURETRAL.
ES90902952T 1989-01-27 1990-01-19 Formula y metodo para el tratamiento de hipertrofias prostaticas benignas. Expired - Lifetime ES2072424T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30380989A 1989-01-27 1989-01-27
US42996689A 1989-10-31 1989-10-31

Publications (1)

Publication Number Publication Date
ES2072424T3 true ES2072424T3 (es) 1995-07-16

Family

ID=26973659

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90902952T Expired - Lifetime ES2072424T3 (es) 1989-01-27 1990-01-19 Formula y metodo para el tratamiento de hipertrofias prostaticas benignas.

Country Status (9)

Country Link
US (1) US6296847B1 (es)
EP (1) EP0456724B1 (es)
JP (1) JP3054190B2 (es)
AT (1) ATE121946T1 (es)
AU (1) AU5045690A (es)
DE (1) DE69019141T2 (es)
DK (1) DK0456724T3 (es)
ES (1) ES2072424T3 (es)
WO (1) WO1990008555A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4305460C2 (de) * 1993-02-23 1997-09-04 Albert Dr Scheller Pharmazeutische oder kosmetische, Enzyme enthaltende Zubereitung, Verfahren zu deren Herstellung und deren Verwendung
US7018365B2 (en) 1999-05-21 2006-03-28 Micro Therapeutics, Inc. Threaded syringe with quick stop
US6022539A (en) * 1999-06-03 2000-02-08 Advance Biofactures Of Curacao Amelioration of peyronie's disease
US7063838B1 (en) 1999-09-24 2006-06-20 Proteon Therapeutics Llc Methods for treating an artery or vein in a human subject
PT1220830E (pt) * 1999-09-24 2007-06-11 Proteon Therapeutics Inc Utilização de elastase para abertura de artérias e veias obstruídas
US6428785B1 (en) 1999-10-28 2002-08-06 Immunolytics Inc. Method and composition for treating prostate cancer
US6678391B2 (en) * 2000-04-18 2004-01-13 Matsushita Electric Industrial Co., Ltd. Organism-specimen morphological-change detecting apparatus, and organism-specimen morphological-change detecting method
WO2002074329A1 (en) * 2001-03-19 2002-09-26 Ribeiro Santana Cristiano Albe Pharmaceutical composition applied to the treatment of the peyronie disease and corresponding obtention process
AU2003212195A1 (en) * 2002-02-06 2003-09-02 N-Zyme Biotec Gmbh Protease screening and novel use of proteases
AU2003220115A1 (en) * 2002-05-20 2003-12-12 Board Of Regents, The University Of Texas System Methods and compositions for delivering enzymes and nucleic acid molecules to brain, bone, and other tissues
AU2002333006A1 (en) * 2002-09-19 2004-04-08 Gilberto De Nucci Pharmaceutical composition comprising carriers for products
US7437194B2 (en) * 2003-10-31 2008-10-14 Medtronic, Inc. Stimulating the prostate gland
MXPA03011987A (es) * 2003-12-19 2005-06-23 Osio Sancho Alberto Metodo para el tratamiento de la presbicia induciendo cambios en el poder y fisiologia corneal.
US7572613B2 (en) * 2004-06-25 2009-08-11 Klein Jeffrey A Drug delivery system for accelerated subcutaneous absorption
CN1930186A (zh) 2005-03-03 2007-03-14 阿勒根公司 为获得梭菌毒素的梭菌细菌培养基及方法
KR101447184B1 (ko) * 2006-11-10 2014-10-08 엘아이지에이디피 주식회사 게이트슬릿 개폐장치가 구비된 공정챔버
ES2441961T3 (es) * 2007-02-15 2014-02-07 Allergan, Inc. Composiciones de toxina botulínica y métodos
AT506095A1 (de) * 2007-12-03 2009-06-15 Volopharm Gmbh Verwendung von proteasen
US8449512B2 (en) 2010-04-09 2013-05-28 Davinci Biomedical Research Products Inc. Stoma stabilitating device and method
EP2907504B1 (en) 2011-02-08 2017-06-28 Halozyme, Inc. Composition and lipid formulation of a hyaluronan-degrading enzyme and the use thereof for treatment of benign prostatic hyperplasia
JP6049714B2 (ja) * 2011-07-20 2016-12-21 メディウンド リミテッド 結合組織疾患の治療のためのブロメライン由来タンパク質分解抽出物
US20130178454A1 (en) * 2011-11-17 2013-07-11 Shalender Bhasin Combination of testosterone and ornithine decarboxylase (odc) inhibitors
MX364260B (es) 2012-08-10 2019-04-17 Osio Corp D/B/A Yolia Health Uso de lentes de contacto en el tratamiento de una afección oftalmológica.
WO2019086463A1 (en) 2017-10-30 2019-05-09 Baxalta GmbH Environmentally compatible detergents for inactivation of lipid-enveloped viruses
US10835538B2 (en) * 2018-03-28 2020-11-17 Nymox Corporation Method of treating benign prostatic hyperlasia with antibiotics

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE744162A (fr) 1969-01-16 1970-06-15 Fuji Photo Film Co Ltd Procede d'encapsulage
US3792161A (en) 1970-05-18 1974-02-12 Research Corp Burn ointment comprising silver sulfadiazine and collagenase
US3678158A (en) 1971-05-11 1972-07-18 Worthington Bio Chem Corp Treatment of herniated intervertebral discs of mammals
US4276284A (en) 1971-07-26 1981-06-30 Brown Stuart I Prevention of collagenase induced disease by treatment with collagenase inhibitors
US3977408A (en) 1974-11-01 1976-08-31 Mackew Allan H Prosthetic catheter
US4005194A (en) 1975-06-23 1977-01-25 Abbott Laboratories Treatment of prostatic hyperplasia
US4317818A (en) 1976-05-10 1982-03-02 Richardson-Merrell Inc. Method of treating prostatic carcinoma
DE2655801C2 (de) 1976-12-09 1986-06-26 Kernforschungsanlage Jülich GmbH, 5170 Jülich Injizierbare Suspension von Membranvesikeln aus Erythrozyten und Verfahren zur Herstellung der Suspension
US4174389A (en) 1977-05-13 1979-11-13 Cope Louise A Ophthalmic use of collagenase
CH624011A5 (es) 1977-08-05 1981-07-15 Battelle Memorial Institute
DE2817157A1 (de) 1978-04-17 1979-10-25 Schering Ag Verwendung von antioestrogenen und antigonadotrop wirkenden antiandrogenen zur prophylaxe und therapie der prostatahyperplasie
US4329430A (en) * 1979-06-04 1982-05-11 Klein Gerold K V Enzyme mixture
US4317817A (en) 1979-08-27 1982-03-02 Richardson-Merrell Inc. Novel steroid 5α-reductase inhibitors
US4276281A (en) 1980-09-04 1981-06-30 Crikelair George F Burn treatment
US4338300A (en) 1981-02-05 1982-07-06 The Regents Of The University Of California Use of purified clostridial collangenase in the treatment of Peyronie's disease
JPS5826822A (ja) 1981-08-10 1983-02-17 Kaken Pharmaceut Co Ltd 慢性腎炎治療剤
JPS58189122A (ja) 1982-04-30 1983-11-04 Kaken Pharmaceut Co Ltd 高脂血症予防治療剤
JPS5951221A (ja) 1982-09-17 1984-03-24 Eisai Co Ltd 変形性関節症治療剤
IT1189379B (it) * 1982-10-08 1988-02-04 Serono Ist Farm Composizione farmaceutica contenente un agente fibrinolitico ed un fattore di diffusione,utile per il trattamento dell'infarto miocardico
US4524065A (en) * 1983-08-04 1985-06-18 Bio-Specifics N.V. Method for the prevention and treatment of scars with enzymes
US4645668A (en) * 1983-08-04 1987-02-24 Biospecifics, Nv Method for the prevention and treatment of scars with enzymes
US4659695A (en) * 1985-02-08 1987-04-21 Fernand Labrie Method of treatment of prostate cancer
US4678668A (en) * 1985-10-28 1987-07-07 Md Associates Method of reducing soft tissue swelling and pain
US5116615A (en) * 1989-01-27 1992-05-26 Immunolytics, Inc. Method for treating benign prostatic hypertrophy

Also Published As

Publication number Publication date
US6296847B1 (en) 2001-10-02
DK0456724T3 (da) 1995-10-02
DE69019141D1 (de) 1995-06-08
JPH04503071A (ja) 1992-06-04
ATE121946T1 (de) 1995-05-15
EP0456724B1 (en) 1995-05-03
EP0456724A1 (en) 1991-11-21
WO1990008555A1 (en) 1990-08-09
DE69019141T2 (de) 1996-01-18
JP3054190B2 (ja) 2000-06-19
AU5045690A (en) 1990-08-24
HK1003981A1 (en) 1998-11-13

Similar Documents

Publication Publication Date Title
DK0456724T3 (da) Præparat og fremgangsmåde til behandling af benign prostatisk hypertrofi
ES2170141T3 (es) 4-aminoderivados del acido micofenolico con actividad inmunosupresora.
ATE373483T1 (de) Zusammensetzung zur behandlung von prostatakrebs
ES2168359T3 (es) Acido micofenolico 6-sustituido y derivados con actividad inmunosupresora.
DK1140078T3 (da) Vaskulærskadende benzimidazolmidler
CO5011115A1 (es) Compuestos y metodos quimioquina
AR027234A1 (es) Derivados de la toxina clostridial y metodos para el tratamiento del dolor
TR199801151T2 (xx) Trombin inhibit�r� �n ila�lar.
FI952607A0 (fi) Farmakologisesti aktiiviset pyridiinijohdannaiset ja menetelmät niiden valmistamiseksi
PT1238141E (pt) Fibras de sementes de plantas e seu uso
ATE249214T1 (de) Pentafluorobenzensulfonamide und analoge
PT1086702E (pt) Neurotoxinas pre-sinapticas para tratamento da dor de cabeca devida a enxaqueca
ES2149971T3 (es) Derivados 5-sustituidos del acido micofenolico.
ATE173603T1 (de) Behandlung von erektionversagen
AR023129A1 (es) Composiciones para mejorar la fertilidad
EA200100376A1 (ru) Арилсульфонанилидмочевины
MX9401312A (es) Nuevo procedimiento para la elaboracion del liofilizado cetrorelix.
EA200101089A1 (ru) Новый способ лечения
ES2143132T3 (es) Monohidratos de derivado de acido aminobenceno-sulfonico y su metodo de preparacion.
ES2174921T3 (es) Inhibidores de la proteasa del vih.
SE0001914D0 (sv) Förbättring av Peyronies sjukdom
ES2163506T3 (es) Derivados de bencimidazolona con actividad dopaminergica central.
ES2133289T3 (es) Aumento en los niveles de glutation con glutamina.
ES2123873T3 (es) Pirrolocarbazol.
MY118986A (en) Use of (alpha)-1-adrenoreceptor antagonists in the prevention and treatment of benign prostatic hyperplasia

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 456724

Country of ref document: ES